Comparison of the Effects of Prizidilol and Propranolol on Renal Haemodynamics at Rest and During Exercise

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1984 Mar 1

PMID 6712858

Citations 1

Authors

P L Malini

E Strocchi

E Ambrosioni

Affiliations

Soon will be listed here.

Abstract

Effective renal plasma flow and glomerular filtration rate were measured in 22 mild-to-moderate, uncomplicated, essential hypertensive patients during placebo and after 3 months of randomly assigned treatment either with prizidilol (n = 10) or propranolol (n = 12). Measurements were performed at rest and during cycloergometer exercise. For a comparable effect on blood pressure effective renal plasma flow was significantly increased at rest by prizidilol (+9%) and decreased by propranolol (-13.6%); these patterns were maintained during exercise. Glomerular filtration rate was immodified after the treatment with both drugs. It is concluded that prizidilol is an effective hypotensive agent with no deleterious effects on renal haemodynamics.

Citing Articles

How Do Antihypertensive Drugs Work? Insights from Studies of the Renal Regulation of Arterial Blood Pressure.

Digne-Malcolm H, Frise M, Dorrington K Front Physiol. 2016; 7:320.

PMID: 27524972 PMC: 4965470. DOI: 10.3389/fphys.2016.00320.

References

PRITCHARD W, ECKSTEIN R, MACINTYRE W, Dabaj E . Correlation of renal blood flow determined by the single injection of Hippuran-I 131 with direct measurements of flow. Am Heart J. 1965; 70(6):789-96. DOI: 10.1016/0002-8703(65)90334-0. View

Cohen M, Smith Jr F, Mindell R, Vernier R . A simple, reliable method of measuring glomerular filtration rate using single, low dose sodium iothalamate I-131. Pediatrics. 1969; 43(3):407-15. View

Falch D, ODEGAARD A, Norman N . Renal plasma flow and cardiac output during hydralazine and propranolol treatment in essential hypertension. Scand J Clin Lab Invest. 1978; 38(2):143-6. DOI: 10.1080/00365517809156082. View

Mason W, Kochak G, Winer N, Cohen I . Effect of exercise on renal clearance of atenolol. J Pharm Sci. 1980; 69(3):344-5. DOI: 10.1002/jps.2600690325. View

Roberts M, Denton M . Effect of posture and sleep on pharmacokinetics. I. Amoxycillin. Eur J Clin Pharmacol. 1980; 18(2):175-83. DOI: 10.1007/BF00561587. View

Leonetti G, Terzoli L, Sala C, Bianchini C, Zanchetti A . Dose-response curve and time course of the antihypertensive effect of SKF 92 657, a beta-receptor-blocking and vasodilating compound. Clin Sci (Lond). 1980; 59 Suppl 6:461s-463s. DOI: 10.1042/cs059461s. View

Collier J, Pitcher D . Investigation of a combined arteriolar dilator and beta-adrenoceptor antagonist (SK & F 92657) in the peripheral vessels of man. Br J Clin Pharmacol. 1980; 10(6):567-71. PMC: 1430227. DOI: 10.1111/j.1365-2125.1980.tb00512.x. View

Larsson R, Karlberg B, Norlander B, Wirsen A . Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther. 1981; 29(5):588-93. DOI: 10.1038/clpt.1981.82. View

Taylor E, Cameron D, EDEN R, FIELDEN R, Owen D . Hemodynamic profile of a new antihypertensive agent D,L-3-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine (SK&F 92657). J Cardiovasc Pharmacol. 1981; 3(2):337-54. DOI: 10.1097/00005344-198103000-00012. View

10.

Koch-Weser J, Frishman W . beta-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305(9):500-6. DOI: 10.1056/NEJM198108273050907. View

11.

Britton K . Essential hypertension: a disorder of cortical nephron control. Lancet. 1981; 2(8252):900-2. DOI: 10.1016/s0140-6736(81)91393-3. View

12.

Wilkinson R . Beta-blockers and renal function. Drugs. 1982; 23(3):195-206. DOI: 10.2165/00003495-198223030-00002. View

13.

Malini P, Strocchi E, Negroni S, Ambrosioni E, Magnani B . Renal haemodynamics after chronic treatment with labetalol and propranolol. Br J Clin Pharmacol. 1982; 13(1 Suppl):123S-126S. PMC: 1401827. DOI: 10.1111/j.1365-2125.1982.tb01900.x. View

14.

Textor S, Fouad F, Bravo E, TARAZI R, Vidt D, GIFFORD Jr R . Redistribution of cardiac output to the kidneys during oral nadolol administration. N Engl J Med. 1982; 307(10):601-5. DOI: 10.1056/NEJM198209023071007. View

15.

Luscher T, Havelka J, Greminger P, Tuma J, Tauber M, Siegenthaler W . Prizidilol (SK & F 92657), a new vasodilator with beta-blocking properties in the treatment of essential hypertension. Eur J Clin Pharmacol. 1982; 23(5):411-5. DOI: 10.1007/BF00605990. View

16.

Lund-Johansen P, Omvik P . Prizidilol in essential hypertension: long-term effects on plasma volume, extracellular fluid volume, and central hemodynamics at rest and during exercise. J Cardiovasc Pharmacol. 1982; 4(6):1012-7. View

17.

Boehringer K, Weidmann P, Link L, Bianchetti M, Schiffl H, REUBI F . Acute effects of combined vasodilation and beta-adrenoceptor blockade with prizidilol on renal function. Br J Clin Pharmacol. 1983; 15(2):181-8. PMC: 1427868. DOI: 10.1111/j.1365-2125.1983.tb01484.x. View

18.

VANDERKOLK K, Dontas A, HOOBLER S . Renal and hypotensive effects of acute and chronic oral treatment with 1-hydrazinophthalazine (apresoline) in hypertension. Am Heart J. 1954; 48(1):95-101. DOI: 10.1016/0002-8703(54)90277-x. View